Northwest Biotherapeutics, Inc. (NWBO)

OTCMKTS · Delayed Price · Currency is USD

0.1919

+0.0019 (1.00%)

Apr 23, 2026, 3:57 PM EST

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Discover and Develop Innovative Immunotherapies for Cancer			1.93M	1.68M	1.01M	1.29M	2.41M
Discover and Develop Innovative Immunotherapies for Cancer Growth			14.80%	67.46%	-22.15%	-46.43%	484.95%
Total			1.93M	1.68M	1.01M	1.29M	2.41M
Total Growth			14.80%	67.46%	-22.15%	-46.43%	484.95%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States			1.93M	1.68M	1.01M	1.29M	2.41M
United States Growth			14.80%	67.46%	-22.15%	-46.43%	484.95%
Total			1.93M	1.68M	1.01M	1.29M	2.41M
Total Growth			14.80%	67.46%	-22.15%	-46.43%	484.95%

Source: S&P Global Market Intelligence.